ANGLE Shares Rise As Pelvic Mass Test Scores High Prediction Rate

LONDON (Alliance News) - Liquid biopsy firm ANGLE PLC shares climbed on Monday as it said results from a study into is pelvic mass triage test showed a high proportion of correct cancer predictions.

ANGLE shares were 15% higher on Monday morning, at 52.99 pence each.

The results, which were presented at the Annual Meeting on Women's Cancer in New Orleans which runs from Saturday to Tuesday, show a correct cancer prediction rate of 95%.

The triage test is used in combination with multiple serum markers to try and predict cancer in women with a pelvic mass or ovarian cyst, ANGLE said.

Chief Executive Andrew Newland said: "The results presented at SGO are a major endorsement for ANGLE. The excellent performance of ANGLE's Parsortix system in this large scale clinical study for the detection of ovarian cancer demonstrates the capability of ANGLE's CTC system to out-perform current approaches for the detection of ovarian cancer.

"ANGLE is now working to bring this clinical application to the market. This study is an exemplar of the level of accuracy that can be achieved with the Parsortix liquid biopsy tests as we simultaneously progress applications in metastatic breast cancer and prostate cancer."